✦ LIBER ✦

Effect of combination therapy with ribavirin and high-dose interferon-α2b for 24 weeks in chronic hepatitis C

✍ Scribed by Shintaro Abe; Ryoichi Narita; Takeshi Oto; Akinari Tabaru; Makoto Otsuki

Book ID: 108950682
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 146 KB
Volume: 21
Category: Article
ISSN: 0815-9319
DOI: 10.1111/j.1440-1746.2006.04173.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment effects and predictors of a 24

Treatment effects and predictors of a 24-week course of interferon α-2b plus ribavirin combination therapy for patients with chronic hepatitis C

✍ Masahiko Tomimatsu; Yoshio Aizawa; Yoshimichi Chuganji; Hideo Ishizuka; Yoshiyuk 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

Effect of lactoferrin in patients with c

Effect of lactoferrin in patients with chronic hepatitis C: Combination therapy with interferon and ribavirin

✍ Masahiko Kaito; Motoh Iwasa; Naoki Fujita; Yoshinao Kobayashi; Yuji Kojima; Jiro 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 159 KB

Cost effectiveness of interferon α2b com

Cost effectiveness of interferon α2b combined with ribavirin for the treatment of chronic hepatitis C

✍ Zobair M. Younossi; Mendel E. Singer; John G. McHutchison; Kenneth M. Shermock 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 1 views

## Treatment of chronic hepatitis C with Interferon (IFN) ␣2b monotherapy results in 10% to 15% sustained virological response (SVR). Combining IFN with ribavirin increases this response. In this analysis, using the Markov model, 6 treatment strategies for chronic hepatitis C (previously untreated

Investigation of hyperuricemia during pe

Investigation of hyperuricemia during pegylated-interferon-α2b plus ribavirin combination therapy in patients with chronic hepatitis C

✍ Naoki YAMASHITA; Munechika ENJOJI; Kazuhiro KOTOH; Masaki KATO; Akihiro UEDA; Yu 📂 Article 📅 2008 🏛 Wiley (Blackwell Publishing) 🌐 English ⚖ 122 KB

Eicosapentaenoic Acid Supplementation fo

Eicosapentaenoic Acid Supplementation for Chronic Hepatitis C Patients During Combination Therapy of Pegylated Interferon α-2b and Ribavirin

✍ Aiko Kawashima; Ikuyo Tsukamoto; Tomoko Koyabu; Yasuko Murakami; Takayo Kawakami 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 255 KB

Factors contributing to ribavirin dose r

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

✍ Shintaro Takaki; Akihito Tsubota; Tetsuya Hosaka; Norio Akuta; Takashi Someya; M 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 209 KB